Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET
Tokenization is becoming more popular with the increase in already tokenized real-world data sets and innovative methods for collecting data. This presentation aims to answer when, why and how patients are tokenized in these newer methods and what happens with the patients and their tokens.
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1582141&tp_key=0213c1b8e0
Event Overview:
The ability to link disparate datasets with de-identified or anonymized patient data has existed for decades but has been unrealistic to apply at scale. Tokenization is becoming more popular with the increase in already tokenized real-world data sets and innovative methods for collecting data. When, why, and how patients are tokenized in these newer methods and what happens with the patients and their tokens are still new to the industry. This presentation aims to answer those on-the-ground application questions.
Key Learning Objectives:
Speakers:
Mariah Baltezegar
VP and Global Head PPAS & RWE
Specialized Solutions
PPD
Mariah Baltezegar leads the Peri- and Post-Approval Studies (PPAS) and Real-World Evidence (RWE) Specialized Solutions team. As an executive member of the PPAS & RWE leadership team, she is responsible for direction of the PPAS & RWE innovation hub and new offering incubation as well as oversight of key operational, commercial and business optimization activities supporting the overall PPAS & RWE business unit. Over the last 20 years, she has held various positions of increasing responsibility across the Thermo Fisher (PPD) enterprise all with a strategic eye for efficiency through process or technology, maximizing the study participant and site experience while ensuring high quality customer results. Mariah completed her Master of Business Administration at the University of North Carolina, Wilmington and holds a bachelor's degree in psychology with a minor in statistics from Winona State University.
Christine Varner
Senior Director, PPAS & RWE Non-
Interventional Studies
PPD
Christine Varner, BS, is a non-interventional studies lead on the Peri- and Post-Approval Studies (PPAS) and Real-World Evidence (RWE) team at Thermo Fisher (PPD). She is a member of the PPAS & RWE Senior Leadership Team, with overall accountability for the strategic talent growth strategy and operational performance of a team of Oversight Directors and Project Leads; drives leadership across performance in relation to financial stewardship, operational delivery and risk management, ensuring compliance with Thermo Fisher (PPD) process. Christine holds a bachelor’s degree in biology with a minor in chemistry from the University of North Carolina at Chapel Hill.
Time and Date:
Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET
Sponsors:
Evidera
PPD
Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1582141&tp_key=0213c1b8e0
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.